Business Context and Reporting Period
This Form 8-K is a current report filed by BioSig Technologies, Inc. (not Streamex Corp.) on December 21, 2018. The filing addresses corporate governance changes, specifically the election of a Lead Director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation and board appointments.
Material Changes
The primary material change is the appointment of Jeffrey F. O'Donnell as Lead Director, effective January 1, 2019, for a one-year term. This appointment includes new compensatory arrangements:
- Cash compensation of $8,000 per month.
- Award of 30,000 shares of restricted common stock, vesting on January 1, 2020.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document is limited to the disclosure of the director's appointment and associated compensation.
Investor Verification Checklist
- Verify the total equity dilution impact of the 30,000 restricted shares awarded to Mr. O'Donnell.
- Confirm the total annual cash cost of the Lead Director role ($96,000) against the company's current cash position.
- Review the full Board composition to understand the governance structure following this appointment.
- Check subsequent filings for the actual vesting of the restricted stock in January 2020.